Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERVGet Free Report) in a report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price objective on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a research report on Thursday, May 2nd.

Read Our Latest Analysis on Minerva Neurosciences

Minerva Neurosciences Price Performance

NERV opened at $3.44 on Wednesday. The company’s 50 day moving average price is $2.69 and its two-hundred day moving average price is $4.75. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49. The firm has a market capitalization of $24.06 million, a price-to-earnings ratio of -0.77 and a beta of 0.13.

Minerva Neurosciences (NASDAQ:NERVGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.07. As a group, equities research analysts predict that Minerva Neurosciences will post -1.89 EPS for the current year.

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Featured Stories

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.